TEVA-PRAZOSIN 1 MG
PRAZOSIN (PRAZOSIN HYDROCHLORIDE) : 1 MG · DIN 01934198 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-PRAZOSIN?
TEVA-PRAZOSIN 1 MG contains PRAZOSIN (PRAZOSIN HYDROCHLORIDE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 01934198, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Oct-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-PRAZOSIN used for?
TEVA-PRAZOSIN (prazosin hydrochloride tablets) is indicated for the treatment of mild to moderate essential hypertension. It is employed in a general treatment program in association with a thiazide diuretic and/or other antihypertensive agents as needed for proper patient response. TEVA-PRAZOSIN may be tried as a sole therapy in those patients in whom treatment with other agents caused adverse effects or is inappropriate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is TEVA-PRAZOSIN called?
The same molecule, PRAZOSIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Prazosin | Latin | Australia |
| Minipress | Latin | Australia |
| Pratsiol | Latin | South Africa |
| Prazosin | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 01934198 |
|---|---|
| Brand name | TEVA-PRAZOSIN |
| Generic / active ingredient | PRAZOSIN (PRAZOSIN HYDROCHLORIDE) : 1 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C02CA01 PRAZOSIN |
| AHFS class | 24:20.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Oct-2011 |
| Original market date | 1992-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 01934198 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1934198 |
| Brand name | TEVA-PRAZOSIN |
| Active ingredient / INN | PRAZOSIN (PRAZOSIN HYDROCHLORIDE) : 1 MG |
| ATC code | C02CA01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C02 |
| AHFS class | 24:20.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it administered?
Starting dose 0.5 mg. Increase gradually to 1 mg b.i.d. or t.i.d. for 3 days. Max daily dose 20 mg. Administer with food, preferably with evening meal.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Bottles of 100
Which pack is which?
| Strength on the label | 1 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | Bottles of 100 |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Known sensitivity to prazosin, other quinazolines, or any ingredient in the formulation.
Warnings and precautions
May cause syncope and excessive hypotension with sudden loss of consciousness (0.8% incidence). Risk of priapism (rare). Caution with initial dose and dosage increases.
What can be used instead?
Other Canadian products sharing ATC code C02CA01 PRAZOSIN. 6 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-PRAZO | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 00882801 |
| APO-PRAZO | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 00882828 |
| APO-PRAZO | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 00882836 |
| TEVA-PRAZOSIN | 2 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01934201 |
| TEVA-PRAZOSIN | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01934228 |
| ALTI-PRAZOSIN-TAB 1MG | 1 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 02139979 |
| ALTI-PRAZOSIN-TAB 2MG | 2 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 02139987 |
| ALTI-PRAZOSIN-TAB 5MG | 5 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 02139995 |
| MINIPRESS | 1 MG | TABLET | AA PHARMA INC | DORMANT | DIN 00560952 |
| MINIPRESS | 2 MG | TABLET | AA PHARMA INC | DORMANT | DIN 00560960 |
Who else supplies PRAZOSIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PRAZOSIN appears in 36 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does PRAZOSIN cost around the world?
PRAZOSIN is listed on 5 national price registers Nexara tracks, across 95 pack listings published on 5 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 3 | 71 | 03 Sep 2026 |
| Australia | ex-manufacturer | 3 | 14 | 08 Sep 2026 |
| Saudi Arabia | public | 3 | 6 | 01 Sep 2026 |
| South Africa | single exit price | 2 | 3 | 01 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.